|View printer-friendly version|
|December 04, 2001 11:40 a.m.|
|Teva and Proneuron Biotechnologies Entered into an Agreement to Develop glatiramer acetate for Multiple Neurodegenerative Diseases|
New uses of glatiramer acetate - the active ingredient of Copaxone® - as a potential neuroprotective agent to be developed under this agreement
Jerusalem, Israel, December 4, 2001 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), today announced that Teva and Proneuron Biotechnologies Inc., entered into a strategic alliance agreement that includes the potential development and exclusive commercialization of glatiramer acetate for diseases which may be treatable with a neuroprotective agent. These include Alzheimer's Disease, stroke, brain trauma, glaucoma, Parkinson's Disease, peripheral neuropathy, and others.